Shandong Lukang Pharmaceutical Co.,Ltd.

Equities

600789

CNE000000P61

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
7.14 CNY +10.02% Intraday chart for Shandong Lukang Pharmaceutical Co.,Ltd. +20.20% -.--%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lukang Pharmaceutical Gets Nod to Produce Parkinson's Disease Drug MT
Lukang Pharmaceutical's Piperacillin Sodium, Tazobactam Sodium Injection Passes Regulatory Evaluation MT
Lukang Pharmaceutical's Ampicillin Sodium and Sulbactam Sodium Pass Regulatory Evaluation MT
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Lukang Pharmaceutical's Ornidazole Tablets Passes Regulatory Evaluation MT
Shandong Lukang Pharmaceutical Co.,Ltd.(XSSC:600789) added to S&P Global BMI Index CI
Lukang Pharma Generic Hypertension Drug Passes Regulatory Evaluation MT
Lukang Pharmaceutical's Cefaclor Granules Passes Chinese Drug Regulator's Evaluation MT
Lukang Pharmaceutical's Cefixime Tablets Passes Regulator's Evaluation MT
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Lukang Pharmaceutical's Cefminox Sodium for Injection Passes Regulatory Evaluation MT
Lukang Pharmaceutical's Cefaclor Capsules Passes Regulatory Evaluation MT
Lukang Pharma's Cefazolin Sodium for Injection Passes Drug Regulator's Evaluation MT
Lukang Pharma's Ampicillin Sodium for Injection Passes Regulatory Evaluation MT
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Lukang Pharma Gets Nod to Market Anti-Arthritis Drug Ingredient MT
Lukang Pharma’s Benzyl Alcohol Wins Marketing Approval in China MT
Shandong Lukang Pharmaceutical Raising 1.2 Billion Yuan to Fund Expansion Plans MT
Lukang Pharma Gets Regulatory Nod for Anti-Pneumonia Drug MT
Lukang Pharmaceutical Gets Approval for Diabetes Treatment Tablet MT
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Shandong Lukang Pharmaceutical Co.,Ltd. acquired remaining 60% stake in Shandong Lukang Zhonghe Environmental Protection Technology Co., Ltd. from Hualu Holdings Co., Ltd CI
Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Chart Shandong Lukang Pharmaceutical Co.,Ltd.
More charts
Shandong Lukang Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The Company's primary products include pharmaceutical preparation products, semi-synthetic antibiotic raw materials, veterinary antibiotics and antibiotic raw materials and others. The Company is also involved in the production and distribution of pharmaceutical intermediates. The Company distributes its products in domestic and overseas markets.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 600789 Stock
  4. News Shandong Lukang Pharmaceutical Co.,Ltd.
  5. Lukang Pharmaceutical's Piperacillin Sodium, Tazobactam Sodium Injection Passes Regulatory Evaluation